Literature DB >> 21052639

Association of SMAD2 polymorphisms with bone mineral density in postmenopausal Korean women.

B-J Kim1, J-Y Hwang, B-G Han, J-Y Lee, J Y Lee, E K Park, S H Lee, Y-E Chung, G S Kim, S-Y Kim, J-M Koh.   

Abstract

UNLABELLED: In a candidate gene association study, we found that SMAD2 promoter alleles and haplotypes were significantly associated with bone mineral density (BMD) at the lumbar spine and various proximal femur sites. Our results suggest that SMAD2 polymorphisms may be one of genetic determinants of BMD in postmenopausal women.
INTRODUCTION: SMAD2, which is the specific intracellular transducer of TGF-ß, is thought to participate in bone metabolism by playing a critical role in the development and function of osteoclasts and osteoblasts. We performed association analyses of the genetic variation in SMAD2 to ascertain the contribution of this gene to BMD and risk of osteoporotic fracture.
METHODS: We selected three SMAD2 promoter single-nucleotide polymorphisms (SNPs) based on heterozygosity and validation status. Postmenopausal Korean women (n = 1,329) were genotyped for these SNPs, and their BMD and risk of fractures were assessed. BMD at the lumbar spine and proximal femur was measured using dual-energy X-ray absorptiometry. P values were corrected for multiple testing by the effective number of independent marker loci (P (cor)).
RESULTS: We found that SMAD2 -35302C>T, -34952A>G, and ht2 were significantly associated with BMD at both the lumbar spine and femur neck (P (cor) = 0.020-0.046), whereas SMAD2 -36201A>G and ht1 affected the femur neck BMD (P (cor) = 0.018-0.031). The genetic effects of these three polymorphisms on BMD at the lumbar spine and femur neck were risk-allele dependent in additive model. The three polymorphisms and two hts were also significantly associated with BMD at other proximal femur sites, such as the total femur, trochanter, and femur shaft (P (cor) = 0.001-0.046). However, none of the polymorphisms or hts was associated with an increased risk of fracture.
CONCLUSIONS: Our results suggest that SMAD2 polymorphisms may be one of genetic determinants of BMD in postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21052639     DOI: 10.1007/s00198-010-1450-8

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  36 in total

Review 1.  Genetics of osteoporosis.

Authors:  J A Eisman
Journal:  Endocr Rev       Date:  1999-12       Impact factor: 19.871

Review 2.  Osteophyte formation in the vertebral column: a review of the etiologic factors--Part II.

Authors:  M Nathan; M H Pope; L J Grobler
Journal:  Contemp Orthop       Date:  1994-08

3.  Genetic determinants of bone mass in adult women: a reevaluation of the twin model and the potential importance of gene interaction on heritability estimates.

Authors:  C W Slemenda; J C Christian; C J Williams; J A Norton; C C Johnston
Journal:  J Bone Miner Res       Date:  1991-06       Impact factor: 6.741

4.  Local administration of activin promotes fracture healing in the rat fibula fracture model.

Authors:  R Sakai; K Miwa; Y Eto
Journal:  Bone       Date:  1999-08       Impact factor: 4.398

5.  Megakaryocyte-mediated inhibition of osteoclast development.

Authors:  Melissa A Kacena; Tracy Nelson; Mary E Clough; Sun-Kyeong Lee; Joseph A Lorenzo; Caren M Gundberg; Mark C Horowitz
Journal:  Bone       Date:  2006-06-16       Impact factor: 4.398

Review 6.  Transforming growth factor-beta1 to the bone.

Authors:  Katrien Janssens; Peter ten Dijke; Sophie Janssens; Wim Van Hul
Journal:  Endocr Rev       Date:  2005-05-18       Impact factor: 19.871

7.  Decreased bone mass and bone elasticity in mice lacking the transforming growth factor-beta1 gene.

Authors:  A G Geiser; Q Q Zeng; M Sato; L M Helvering; T Hirano; C H Turner
Journal:  Bone       Date:  1998-08       Impact factor: 4.398

Review 8.  Smad signaling in skeletal development and regeneration.

Authors:  Buer Song; Kristine D Estrada; Karen M Lyons
Journal:  Cytokine Growth Factor Rev       Date:  2009 Oct-Dec       Impact factor: 7.638

9.  Transforming growth factor-beta1 (TGF-beta1) induces human osteoclast apoptosis by up-regulating Bim.

Authors:  Nicolas Houde; Estelle Chamoux; Martine Bisson; Sophie Roux
Journal:  J Biol Chem       Date:  2009-07-01       Impact factor: 5.157

10.  The role of gap junctions in megakaryocyte-mediated osteoblast proliferation and differentiation.

Authors:  Wendy A Ciovacco; Carolyn G Goldberg; Amanda F Taylor; Justin M Lemieux; Mark C Horowitz; Henry J Donahue; Melissa A Kacena
Journal:  Bone       Date:  2008-09-10       Impact factor: 4.398

View more
  3 in total

1.  Polydopamine coating with static magnetic field promotes the osteogenic differentiation of human bone-derived mesenchymal stem cells on three-dimensional printed porous titanium scaffolds by upregulation of the BMP-Smads signaling pathway.

Authors:  Lingpeng Kong; Yong Han; Qingsen Lu; Dongsheng Zhou; Bomin Wang; Dawei Wang; Wupeng Zhang; Hao Xiang; Mingzhen Li; Fu Wang
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

2.  Meta-analysis identifies a MECOM gene as a novel predisposing factor of osteoporotic fracture.

Authors:  Joo-Yeon Hwang; Seung Hun Lee; Min Jin Go; Beom-Jun Kim; Ikuyo Kou; Shiro Ikegawa; Yan Guo; Hong-Wen Deng; Soumya Raychaudhuri; Young Jin Kim; Ji Hee Oh; Youngdoe Kim; Sanghoon Moon; Dong-Joon Kim; Heejo Koo; My-Jung Cha; Min Hye Lee; Ji Young Yun; Hye-Sook Yoo; Young-Ah Kang; Eun-Hee Cho; Sang-Wook Kim; Ki Won Oh; Moo Il Kang; Ho Young Son; Shin-Yoon Kim; Ghi Su Kim; Bok-Ghee Han; Yoon Shin Cho; Myeong-Chan Cho; Jong-Young Lee; Jung-Min Koh
Journal:  J Med Genet       Date:  2013-01-24       Impact factor: 6.318

3.  Association of Bone Morphogenetic Protein (BMP)/Smad Signaling Pathway with Fracture Healing and Osteogenic Ability in Senile Osteoporotic Fracture in Humans and Rats.

Authors:  De-Bao Liu; Cong Sui; Ting-Ting Wu; Lian-Zhong Wu; You-Yu Zhu; Zhen-Hua Ren
Journal:  Med Sci Monit       Date:  2018-06-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.